Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 3, 2025
– $45.9 million in total revenue, representing 21% growth over 2Q25 –
– $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand –
Read more at globenewswire.com
